Arbutus Biopharma Reports Robust Q1 with $169.7M Net Income from Moderna Settlement, Plans Shareholder Capital Return

summarizeSummary

Arbutus Biopharma reported a significant financial turnaround in Q1 2026, driven by a $178.7 million payment from the Moderna patent settlement, leading to a net income of $169.7 million and plans for a shareholder capital return.

check_boxKey Events

• Strong Q1 Financial Performance

  Reported a net income of $169.7 million for Q1 2026, a substantial improvement from a net loss of $(24.5) million in Q1 2025. Basic EPS was $0.88 and diluted EPS was $0.87.

• Moderna Settlement Payment Recognized

  Recognized $178.7 million in license revenue from Genevant, representing Arbutus's portion of the $950.0 million noncontingent Moderna patent settlement payment, expected by July 8, 2026.

• Significant Liquidity Boost

  Cash, cash equivalents, and marketable securities totaled $95.2 million as of March 31, 2026, supplemented by a $178.7 million license receivable from Genevant, significantly strengthening the balance sheet.

• Planned Shareholder Capital Return

  The company is evaluating a return of capital to shareholders in Q3 2026, following the receipt of its portion of the Moderna settlement payment.

auto_awesomeAnalysis

Arbutus Biopharma's Q1 2026 results mark a significant financial turnaround, primarily driven by the $178.7 million noncontingent payment from the Moderna patent settlement. This influx of funds has dramatically improved the company's liquidity, boosting total current assets to $277.0 million and resulting in a net income of $169.7 million, a stark contrast to the loss in the prior year. The company's plan to return capital to shareholders in Q3 2026, following the receipt of the settlement payment, is a strong positive signal for investors. Additionally, the FDA's Fast Track designation for imdusiran and the ongoing Pfizer/BioNTech litigation with a favorable claim construction ruling provide further positive momentum, outweighing the negative impact of a European patent revocation which the company plans to appeal.